401results about How to "Low chance of recurrence" patented technology

The invention belongs to the field of genetic engineering, and concretely relates to a BCMA-targeting chimeric antigen receptor and an application thereof. The chimeric antigen receptor comprises an antigen recognition region, a hinge region, a transmembrane region and an intracellular signal domain; and the amino acid sequence of an extracellular recognition region is represented by SEQ ID NO.1 or SEQ ID NO.2 or SEQ ID NO.3. The chimeric antigen receptor can effectively remove BCMA-expressing tumor target cells after being expressed in immune cells, has no toxic or side effects on antigen-negative cells, and can be used for the targeted therapy of tumors.

The invention provides a PSCA (prostate stem cell antigen) and PD-L1 targeted CAR based on OCTS (one CAR with two ScFvs)-CAR (chimeric antigen receptor), an encoding gene, an OCTS-CAR-T recombinant expression vector as well as a construction method and an application of the OCTS-CAR-T recombinant expression vector. The PSCA and PD-L1 targeted CAR comprises a CD8 leader membrane receptor signal peptide, a double-antigen binding region, a CD8 Hinge chimeric receptor linker, a CD8 Transmembrane chimeric receptor transmembrane region, a CD28 chimeric receptor co-stimulator, an OX40 chimeric receptor co-stimulator and a TCR chimeric receptor T-cell activation domain which are connected in series sequentially, wherein the double-antigen binding region comprises heavy chains VH and light chains VL of PSCA and PDL1 single-chain antibodies, Inner-Linker in antibodies and Inter-Linker among the single-chain antibodies, which are in series connection or turn connection. Besides, the invention provides the encoding gene of the PSCA and PD-L1 targeted CAR, the recombinant expression vector as well as the construction method and the application of the recombinant expression vector.

The invention provides an OCTS-CAR technique-based OCTS-CAR double-targeting chimeric antigen receptor, a coding gene and a recombinant expression vector and establishment and application of the OCTS-CAR double-targeting chimeric antigen receptor, the coding gene and the recombinant expression vector. The OCTS-CAR double-targeting chimeric antigen receptor includes a CD8 leader membrane receptor signal peptide, a double-antigen binding region, a CD8 Hinge chimeric receptor gemel, a CD8 transmembrane chimeric receptor transmembrane region, a CD28 chimeric receptor co-stimulatory factor, a CD134 chimeric receptor co-stimulatory factor and a TCR chimeric receptor T cell activating domain which are connected sequentially and in series, wherein the double-antigen binding region comprises heavy-chain VH and light-chain VL, connected in a certain mode, of two single-chain antibodies, an antibody Inner-Linker and an Inter-Linker between single-chain antibodies, and the two single-chain antibodies are formed by combining any two of a BCMA single-chain antibody, a CD319 single-chain antibody, a CD38 single-chain antibody, a PDL1 single-chain antibody and a CD123 single-chain antibody; in addition, the invention further provides a gene encoding the OCTS-CAR double-targeting chimeric antigen receptor, the recombinant expression vector and an establishment method and application of the gene encoding the OCTS-CAR double-targeting chimeric antigen receptor and the recombinant expression vector.

The invention discloses a moisturizing, whitening, acne removing, grease controlling and relieving skin beautifying composition. The composition is mainly prepared from the following raw materials: raspberry ketone glucoside, arbutin, matrine, fructo-oligosaccharide, tea tree oil, dipotassium glycyrrhizinate, an extracting solution of leaf of Tasmanian bluegum, tea polyphenol, a peony root extract, tremella polysaccharide, hyaluronic acid with low molecular weight, hyaluronic acid with high molecular weight, transparent xanthan gum, zinc gluconate, Carbomer 940, hydroxyethyl cellulose, 1,3-butanediol, nicotinamide, D-panthenol, tranexamic acid, vitamin C ethyl ether, triethanolamine, an emulsifier, water, and the like. The moisturizing, whitening, acne removing, grease controlling and relieving skin beautifying composition has the beneficial effects that the composition is rich in plant essence, is reasonable in proportioning and can achieve the effects of effectively comforting and smoothening pores, cleaning hair follicles, balancing grease excretion, promoting wound healing and ensuring no pockmarks after healing and low recurrence probability; besides, the composition is also rich in moisturizing ingredients, so that the skins can be hydrated and bright, fine lines can be reduced and smooth and fair skins can be restored after the composition is used for a long term.

The invention provides a lost circulation additive for plugging severe mud loss formation fracture and a preparation method of the lost circulation additive. The lost circulation additive comprises the following components in percentage by mass: 45-56% of oil well grade-G cement, 8-12% of gravel, 12-15% of granolithic, 15-20% of fracturing sand, 6-9% of a thin plugging agent, 1-2% of a fluid loss agent and 2-4% of an admixture. According to the lost circulation additive disclosed by the invention, large fractures and large holes of the severe mud loss formation can be well plugged, the problem that the plugging agent cannot be bridged, remained, filled and reinforced in the large fractures can be well solved, and the requirements on drilling construction and environment friendliness are met. Moreover, the preparation method is simple, the operability is high, the severe mud loss plugging effect is obvious, the plugging operation cost is effectively reduced, and the plugging operation time is saved.

The invention provides plugging slurry for enhancing pressure-bearing capacity of leakage formation. The plugging slurry is composed of the following substances (by weight): 55-60% of a curing agent for fiber coagulation, 1-2% of asphalt powder for well drilling, 0.05-0.1% of an oil well cement defoamer and 38-45% of water. The invention also provides a plugging method capable of enhancing pressure-bearing capacity of leakage formation during petroleum drilling process. The method has a good plugging effect on medium and large-scale lost circulation and meets requirements of drilling construction and environmental protection. The plugging technology requires fewer types of chemical materials, and the method for preparation of the plugging slurry is simple. A pressure-bearing squeeze plugging method has strong operationality. The product has a good effect of plugging fractures and pores of a leakage zone and can obviously reduce lost circulation velocity of the leakage zone. Plugging time is greatly shortened and plugging cost is greatly reduced.

The invention discloses a lymphoblastic leukemia CAR-T (Chimeric Antigen Receptor-T Cell Immunotherapy) therapy carrier based on an OCTS (One CAR with Two SeFvs) technology. The lymphoblastic leukemia CAR-T therapy carrier comprises a lentivirus skeleton plasma, a human EF1alpha promoter, an OCTS chimeric receptor structural domain and an IL6R single-chain antibody, wherein the OCTS chimeric receptor structural domain comprises a CD8 leader chimeric receptor signal peptide and two groups of single-chain antibodies; the first group of single-chain antibodies is selected from any one of the following four groups of single-chain antibodies: a CD20 single-chain antibody light chain VL and a CD20 single-chain antibody heavy chain VH, a CD22 single-chain antibody light chain VL and a CD22 single-chain antibody heavy chain VH, a CD30 single-chain antibody light chain VL and a CD30 single-chain antibody heavy chain VH, and a CD123 single-chain antibody light chain VL and a CD123 single-chain antibody heavy chain VH; and the second group of the single-chain antibodies is a CD19 single-chain antibody light chain VL and a CD19 single-chain antibody heavy chain VH, an antibody Inner-Linker, a single-chain antibody Inter-Linker, a CD8-Hinge chimeric receptor linker, a CD8 Transmembrane chimeric receptor transmembrane zone, a TCR (T Cell Receptor) chimeric receptor T cell activation domain and a chimeric receptor co-stimulator zone. Besides, the invention discloses a constructing method for the carrier and application of the carrier to preparation of a drug for treating lymphoblastic leukemia.

The invention discloses an OCTS (One CAR (Chimeric Antigen Receptor) with two ScFvs (Single-chain variable Fragments)) technique based CAR-T (Chimeric Antigen Receptor-T cell immunotherapy) therapeutic vector for glioblastoma. The OCTS technique based CAR-T therapeutic vector comprises a lentiviral skeleton plasmid, a human EF1 [alpha] promoter (SEQ ID NO. 14), an OCTS chimeric receptor structural domain and a PDL1 single-chain antibody, wherein the OCTS chimeric receptor structural domain comprises a CD8 leader chimeric receptor signal peptide (SEQ ID NO. 15), a PDL1 single-chain antibody light chain VL (SEQ ID NO. 16), a PDL1 single-chain antibody heavy chain VH (SEQ ID NO. 17), an EGFRvIII single-chain antibody light chain VL (SEQ ID NO. 18), an EGFRvIII single-chain antibody heavy chain VH (SEQ ID NO. 19), an antibody Inner-Linker (SEQ ID NO. 20), a single-chain antibody Inter-Linker (SEQ ID NO. 21), a CD8 Hinge chimeric receptor linker (SEQ ID NO. 22), a CD8 Transmembrane chimeric receptor transmembrane domain (SEQ ID NO. 23), a TCR (T Cell Receptor) chimeric receptor T cell activation domain (SEQ ID NO. 26) and a chimeric receptor co-stimulator domain. In addition, the invention also discloses a construction method of the vector and application of the vector to the preparation of a medicine for treating the glioblastoma.

The invention discloses a traditional Chinese medicine for treating lung wind blood heat type acne. The traditional Chinese medicine is characterized by comprising the following components in percentage: 20-40% of honeysuckle, 10-30% of fructus forsythiae, 20-40% of dandelion, 20-40% of oldenlandia diffusa, 20-40% of wild chrysanthemum flower, 10-30% of radix scutellariae, 10-30% of polygonum cuspidatum, 10-30% of salvia miltiorrhiza, 10-30% of sophora flower, 10-30% of folium eriobotryae, 10-20% of folium eriobotryae and 10-20% of betel nut. The preparation method comprises the steps of weighing the 12 traditional Chinese medicines according to proportion by weight, and carrying out water decoction with soft fire for two times and combining the decoction liquids, wherein the traditional Chinese medicine is taken orally for two times every day. By combining the 12 traditional Chinese medicines, the traditional Chinese medicine has the effects of dispelling the wind, clearing the heat, activating the blood and cooling the blood, and is mainly used for treating the diseases such as lung wind blood heat type acne and acne rosacea.

The invention belongs to the field of genetic engineering, in particular to a chimeric antigen receptor (CAR) against a CD20 antigen and an application thereof. The CAR against the CD20 antigen is characterized in that the CAR is formed by polypeptides, namely single-chain variable fragment (scFv) for identifying the CD20 antigen, a hinge region, a transmembrane region and intracellular signals ina sequentially connected mode; and the amino acid sequence of the polypeptides (scFv) for identifying the CD20 antigen is shown as SEQ ID NO.14. After the CAR against the CD20 antigen provided by theinvention is expressed in immune cells, tumor target cells expressing the CD20 antigen can be effectively removed, it can be maintained that targeted CD20 molecules are combined with CD20 molecules on the cell surface to achieve the effect of killing B lymphocyte, the ability of multiplication and the ability of CAR-T to kill tumors can be enhanced, the toxic and side effects on antigen-negativecells are avoided, and the CAR can be used for targeted treatment of the tumors.

The invention discloses a Chinese herba preparation for treating a coronary heart disease. The Chinese herba preparation is prepared by the following traditional Chinese medicines in parts by weight: 20-150 parts of salvia miltiorrhiza, 20-100 parts of kudzuvine root, 10-100 parts of ligusticum wallichii, 1-50 parts of radix ophiopogonis, 1-50 parts of ginseng, 1-50 parts of pseudo-ginseng, 1-30 parts of hawthorn, 1-30 parts of trichosanthes kirilowii maxim, 1-30 parts of allium macrostemon and 1-30 parts of flowers carthami. The Chinese herba preparation is an oral preparation, a sub-lingual preparation and an injection preparation. The Chinese herba preparation is in such ways of tablets, capsules, granules, soft capsules, pills, syrups and injections. The salvia miltiorrhiza, the kudzuvine root, the ligusticum wallichii, the radix ophiopogonis, the ginseng, the pseudo-ginseng, the hawthorn, the trichosanthes kirilowii maxim, the allium macrostemon and the flowers carthami are mixed for use in the Chinese herba preparation, so as to obviously alleviate stenocardia and improve myocardial ischemia. The invention further provides a preparation method of the Chinese herba preparation for treating the coronary heart disease. The salvia miltiorrhiza, the kudzuvine root, the ligusticum wallichii, the radix ophiopogonis, the ginseng, the pseudo-ginseng, the hawthorn, the trichosanthes kirilowii maxim, the allium macrostemon and the flowers carthami are crushed proportionally, extracted with ethanol, purified by macroreticular resin, condensed and dried to obtain dried powder and an extract, and finally the preparation is obtained.

The invention relates to an immune nutrition composition and application thereof. The immune nutrition composition disclosed by the invention comprises the following components in parts by weight: 45-50 parts of hydrolyzed small molecular protein, 10-15 parts of water-soluble dietary fiber, 20-25 parts of edible mushrooms extract, 2-5 parts of selenium-enriched yeast, 5-10 parts of fructo oligosaccharides and 0.63-1.8 parts of vitamin. The immune nutrition composition disclosed by the invention can be used in cancer therapy. According to the immune nutrition composition disclosed by the invention, the cancer chemotherapy and radiotherapy tolerance can be improved, and the capability of killing tumor cells by CIK cells can be improved.

The invention studies the physiological action between vagina microorganisms and sperm cells with experimental means, and finds that certain vagina microorganisms can be specifically combined with sperms, so as to make sperms swim slower or even stop moving, or cause change in protein generation level of sperms to further affect the ability of sperms to be combined with eggs. Based on the findings, the invention determines a technical route for improving sperm motility by interfering with vaginal flora; microorganisms which can be well combined with sperms and do not affect basic physiological characters of sperms are selected out, adhesion of microorganisms harmful to sperms is prevented by means of the occupying function of the selected microorganisms, and therefore sperm motility can be improved, so as to relieve or treat infertility. Furthermore, probiotics microorganisms in a microbial agent are helpful for treatment of various diseases caused by vaginal flora dysbacteriosis, the treatment effect is remarkable, relapse probability is low, and popularization prospects are broad.

The invention discloses an OCTS technology-based pancreatic cancer and malignant mesothelioma CAR-T therapy vector. The vector comprises lentivirus framework plasmid, a human EF1alpha promoter (SEQ ID NO. 14), an OCTS chimeric receptor structural domain and a PDL1 single-chain antibody; the OCTS chimeric receptor structural domain comprises CD8 leader chimeric receptor signal peptide (SEQ ID NO. 15), a PDL1 single-chain antibody light chain VL (SEQ ID NO. 16), a PDL1 single-chain antibody heavy chain VH (SEQ ID NO. 17), an MESOTHELIN single-chain antibody light chain VL (SEQ ID NO. 18), an MESOTHELIN single-chain antibody heavy chain VH (SEQ ID NO. 19), an antibody inner linker Inner-Linker (SEQ ID NO. 20), a single-chain antibody inter-linker Inter-Linker (SEQ ID NO. 21), a CD8 Hinge chimeric receptor linker (SEQ ID NO. 22), a CD8Transmembrane chimeric receptor transmembrane domain (SEQ ID NO. 23), a TCR chimeric receptor T-cell activation domain (SEQ ID NO. 26), and a chimeric receptor inducible co-stimulater area. In addition, the invention also discloses a construction method of the vector as well as application of the vector to preparation of medicines for treating pancreatic cancer and malignant mesothelioma.

The invention discloses a user terminal, remote server and system for stroke continuous nursing. The user terminal comprises a data acquisition module, an information output module, a scheme feedbackmodule and a communication module; the data acquisition module is used for remotely acquiring the physiological data of the patient; the information output module is used for displaying a nursing scheme, reminding information and warning information; the nursing scheme is received from the remote server; the remote server is used for acquiring and storing medical records, physiological data and medical information of the patient, and the nursing scheme needed by continuous nursing is generated according to the medical records of the patient; the remote server is further used for generating thereminding information and / or alarm information according to the medical records and / or physiological data; the scheme feedback module is used for feeding back the execution information of the patientfor the nursing scheme to the remote server and / or a preset medical terminal; and a communication module is used for communicating with the remoter server and the medical terminal. According to the method, the whole prevention period of the patient can be subjected to continuous comprehensive medical intervention through the network.

The invention relates to a Chinese medicinal powder for treating pathogenic wind and cough, which is prepared mainly from the following constituents: Chinese ephedra, mulberry bark, perilla fruit, apricot seeds, poria cocos, dried orange peel each 30g, honey-fried licorice root 15g.

The invention discloses an acne removal tool. The acne removal tool comprises a pipe barrel, a core rod is arranged in the pipe barrel, and a piston is arranged at the lower end of the core rod and fixedly connected with the piston; a connector integrated with the pipe barrel is arranged on the lower end face of the pipe barrel, a sleeve is connected to the connector, and an acne removal part is arranged at the lower end of the sleeve; a first air hole is formed in the piston and is a through hole, a first one-way valve is arranged in the first air hole, and a second air hole is formed in thebottom of the pipe barrel and communicated with the pipe barrel and the sleeve; a second one-way valve is arranged in the second air hole. An acne removal needle is used for puncturing an acne on skin, the acne removal part is used for downwards pressing the acne on the skin, when the bottom of the sleeve abuts against the skin, the core rod is pulled to drive the piston to move upwards, the firstone-way valve on the piston is switched off, and the interior of the pipe barrel is negative pressure; the second one-way valve at the bottom of the pipe barrel is switched off, air in the sleeve enters the pipe barrel, the air pressure in the sleeve is reduced, secreta in the acne on the skin can be sucked out, the secreta in the acne can be completely removed, and the relapsing probability of the acne is reduced.

The invention discloses a formula of a traditional Chinese medicine for treating chronic pharyngitis. Unit dosage of the traditional Chinese medicine comprises 15g of radix ophiopogonis, 15g of platycodon grandiflorum, 10g of boat-fruited sterculia seeds, 10g of licorice root, 20g of isatis root, 15g of radix sophorae tonkinensis and 50g of honey. A preparation method of the traditional Chinese medicine comprises weighing radix ophiopogonis, platycodon grandiflorum, boat-fruited sterculia seeds, licorice root, isatis root and radix sophorae tonkinensis according to the above weight ratio, immersing the above materials in 1L of cold water for 20min, decocting the materials through slow fire for 30min and pouring the decoction into a cup with honey, wherein the decoction is taken in three steps, or mixing the decoction and honey and putting the mixture into a vacuum cup, wherein the mixture can be used as tea for slow drinking. The traditional Chinese medicine solves the problem that the conventional treatment drug has a high recurrence rate and large side effect, has a long use period, causes addiction, has a high recurrence rate after drug discontinuance and cannot thoroughly cure diseases. The traditional Chinese medicine is suitable for treating chronic pharyngitis.

The invention relates to a psoriasisvulgaris treating traditional Chinese medicine formula, wherein the components comprise 30 g of buffalo horn, 30 g of isatis tinctoria, 30 g of tuckahoe, 30 g of radix rehmanniae, 10 g of radix paeoniae rubra, 10 g of tree peony bark, 10 g of lonicera japonica, 10 g of cortex dictamni, 10 g of lithospermum erythrorhizon, and 6 g of licorice root. The production and use method comprises that the obtained psoriasisvulgaris treating traditional Chinese medicine is taken through water decoction, one dose of the psoriasisvulgaris treating traditional Chinese medicine is taken a day in three times, and greasy, dampness-heat and spicy food is prohibited during the drug administration process. According to the present invention, the high side effect of the existing psoriasisvulgaris treating drug is solved with the psoriasisvulgaris treating traditional Chinese medicine, and the psoriasisvulgaris treating traditional Chinese medicine is suitable for psoriasisvulgaris treatment.

The invention discloses a myeloid leukemia CAR-T treatment carrier based on an OCTS technology. The myeloid leukemia CAR-T treatment carrier based on the OCTS technology comprises lentivirus framework plasmids, a human EF1 alpha promoter (SEQ ID NO. 14), an OCTS chimeric receptor structural domain and a PDL1 single-chain antibody; the OCTS chimeric receptor structural domain comprises a CD8 leader chimeric receptor signal peptide (SEQ ID NO. 15), a CD33 single-chain antibody light chain VL (SEQ ID NO. 16), a CD33 single-chain antibody heavy chain VH (SEQ ID NO. 17), a CD123 single-chain antibody light chain VL (SEQ ID NO. 18), a CD123 single-chain antibody heavy chain VH (SEQ ID NO. 19), an antibody Inner-Linker (SEQ ID NO. 20), a single-chain antibody Inter-Linker (SEQ ID NO. 21), a CD8 Hinge chimeric receptor hinge (SEQ ID NO. 22), a CD8 Transmembrane chimeric receptor region (SEQ ID NO. 23), a TCR chimeric receptor T cell activation domain (SEQ ID NO. 26) and a chimeric receptor co-stimulatory factor region. In addition, the invention further discloses a construction method of the carrier and application of the carrier in preparation of drugs for treating myeloid leukemia.

The invention discloses a traditional Chinese medicinal compound colloidal bismuth pectin capsule for treating a peptic ulcer and a preparation method thereof. The traditional Chinese medicinal compound colloidal bismuth pectin capsule for treating the peptic ulcer is prepared from the following raw materials in parts by weight: 35-45 parts of colloidal bismuth pectin (metered with the weight of bismuth), 15-25 parts of an acid inhibitor, 50-150 parts of an antibacterial agent, 20-40 parts of ganoderan extracts, 8-15 parts of hydroxypropyl methyl cellulose phthalate, 25-60 parts of a disintegrating agent and 20-60 parts of an emulsifying agent, wherein the acid inhibitor is clad with permethylated-[beta]-cyclodextrin. The obtained capsule is not only good in dispersity and obvious in sustained release effect, but also improves the immunity of an organism, and has an obvious restoring function for the hypoimmunity caused by western medicinal antibiotics.

The invention discloses a medicine for treating habitual abortion. The medicine is characterized by consisting of the following components: radix angelicae sinensis, root of common peony, radix rehmanniae recen, rhizoma ligustici wallichii, liquorice root, folium artemisiae argyi and colla corii asini (melted colla corii asini); the proportions of the components are as follows: 15g of the radix angelicae sinensis, 15g of the root of common peony, 20g of the radix rehmanniae recen, 10g of the rhizoma ligustici wallichii, 10g of the liquorice root, 10g of the folium artemisiae argyi and 10g of the colla corii asini (melted colla corii asini); and methods of preparing and taking the medicine comprise the following steps: weighing the medicinal components according to proportions by weight, decocting the medicinal components, and taking an obtained decoction, one dosage in two times per day. The medicine can solve the problems of an existing habitual abortion treating medicine which is high in side effects, long in medication time, high in recurrence rate after being stopped and the like, and the problem that the existing medicine fails to radically cure the habitual abortion; and the medicine is suitable for treating the habitual abortion.

A medicine for treating irregular menstruation is characterized by comprising the following ingredients: 10g leeches, 10g gadflies, 15g radix et rhizoma rhei and 20g semen persicae. A preparation and administration method comprises the steps of weighing the ingredients by weight percentage, and decocting or pelleting the medicine for administration of one dose per day. The medicine solves the problems that the existing medicine for treating the irregular menstruation has large side effects, the administration time is long, a recurrence rate is high after medicine discontinuance, and the irregular menstruation cannot be radically cured. The medicine is applicable to treatment of the irregular menstruation.

The invention provides graphite oxide nano silver terbinafine antifungal sustained-release thermosensitive hydrogel, and a preparation method and an application of the hydrogel. The graphite oxide nano silver terbinafine antifungal sustained-release thermosensitive hydrogel takes graphite oxide as a drug sustained-release carrier, so that the drug release and action time is prolonged; at the sametime, loaded nano silver can continuously release silver ions to assist in improving an antifungal effect; due to a special sterilization mechanism of the silver ions, a drug resistance problem is notgenerated; the recurrence probability is low; similarly, poloxamer serves as an adjuvant; a drug can be in a liquid state at the room temperature; when the drug is applied to an affected site, the drug is changed into the hydrogel due to temperature rise; the administration is convenient; the contact time of the drug with the affected site can be prolonged; in addition, since the drug exists as anano ingredient, part of the drug can permeate into skin pores in a liquid form and is changed into the hydrogel due to an effect of the body temperature; and the fungicidal action time can be further prolonged.

The invention discloses a drug for treating chronic dyspepsia. The drug is characterized by comprising the following components by weight: 20g of rhizoma atractylodis macrocephalae, 20g of poria cocos, 15g of rhizoma atractylodis, 15g of cortex magnoliae officinalis, 15g of pericarpium citri reticulatae, 10g of rhizoma cyperi, 10g of radix ginseng, 10g of amomum fructus amomi rotundus, 10g of radix aucklandiae, 10g of fructus amomi, 10g of radix liquiritiae and 10g of fructus jujubae. According to a method for preparing and taking the drug, a dose of the drug is taken warmly each day, the radix ginseng can be separately decocted and taken together with the drug, and the rhizoma cyperi is decocted afterwards. The drug solves the problems of great side effect, long taking time, high relapse rate after drug withdrawal, incapability of radically treating chronic dyspepsia and the like for an existing drug for treating chronic dyspepsia, and is suitable for treating the chronic dyspepsia.

A rheumatoid arthritis treatment medicine comprises 200g of willow root, 200g of mulberry root, 200g of Chinese prickly ash root, 200g of alum, 200g of peach root and 200g of Althaea rosea (Linn.) Cavan.. A preparation and taking method of the medicine comprises the following steps: weighing above medicines according to above mass ratio, immersing the medicines for a period of time, decocting the immersed medicines in water with weak fire, taking the obtained medicine decoction, and scrubbing an affected part while hot once every day. The rheumatoid arthritis treatment medicine solves the problems of large side effects, addiction, long taking time, high recurrence rate after medicine discontinuance, and unable radical treatment of present rheumatoid arthritis treatment medicines, and is used to treat the rheumatoid arthritis.

The invention provides a CLL1 and CD33 double-target chimeric antigen receptor and application thereof. The chimeric antigen receptor comprises a signal peptide, an antigen binding domain, a hinge region, a transmembrane domain and a signal transduction domain, and the antigen binding domain comprises an anti-CLL1 single-chain antibody and an anti-CD33 single-chain antibody. According to the constructed CAR molecule simultaneously targeting CLL1 and CD33, the effect of comprehensively targeting acute myelogenous leukemia cells is achieved, the CAR-T cells for expressing CLL1 and CD33 double-target CAR are remarkable in tumor removal effect, the antigen escape phenomenon is avoided, and the CAR molecule has important significance in the field of tumor treatment.

The invention discloses an OCTS technology-based prostatic cancer CAR-T therapy vector which comprises a lentivirus framework plasmid, a human EP1alpha promoter (SEQ ID NO.14), an OCTS chimeric receptor structure domain and a PDL1 single-chain antibody, wherein the OCTS chimeric receptor structure domain comprises A CD8 leader chimeric receptor signal peptide (SEQ ID NO.15), a PSMA single-chain antibody light chain VL (SEQ ID NO.16), a PSMA single-chain antibody heavy chain VH (SEQ ID NO.17), a PDL1 single-chain antibody light chain VL (SEQ ID NO.18), a PDL1 single-chain antibody heavy chain VH (SEQ ID NO.19), an antibody Inner-Linker (SEQ ID NO.20), a single-chain antibody Inter-Linker (SEQ ID NO.21), a CD8 Hinge chimeric receptor hinge (SED ID NO.22), a CD8 Transmembrane chimeric receptor transmembrane domain (SEQ ID NO.23), a TCR chimeric receptor T cell activation domain (SEQ ID NO.26) and a chimeric receptor co-stimulus factor domain. In addition, the invention further discloses a construction method of the vector and an application of the vector in preparation of drugs for treating a prostatic cancer.

Belonging to the field of gene therapy, the invention discloses application of HOXA9 gene in preparation of drugs for treatment of cutaneous squamous cell carcinoma (CSCC). The inventor and the whole team carry out two years of experimental study, adopt cutaneous squamous cell carcinoma characteristic cell line A431 as the experimental object, and perform experiments to find that targeted up-regulation of HOXA9 can inhibit the tumor cell proliferation, migration and invasion ability, also can inhibit tumor cell glycolysis, and ultimately improve or treat cutaneous squamous cell carcinoma. The invention provides a new method for treatment of CSCC on the basis of maximum guarantee of complete organ functions and beautiful appearance, and the method can overcome the shortcomings of the existing technology and has great significance.

The invention relates to medicine for treating endometritis. The medicine is characterized by being prepared from the following ingredients according to the proportion: 15g of radix angelicae sinensis, 15g of peony roots, 20g of radix rehmanniae, 10g of rhizoma chuanxiong, 10g of liquorice roots, 10g of folium artemisiae argyi and 10g of colla corii asini (colla corii asini melted by heat). According to a preparation and medicine taking method, the medical materials are weighed according to the weight ratio; the medicine is decocted; and one dose is taken per day in two times. The medicine solves the problems of great side effects, long medicine taking time, high recurrence rate after the medicine stop, radical cure incapability and the like of the existing medicine for treating endometritis; and the medicine is suitable to be used for treating the endometritis.